Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: Transition Therapeutics Inc. (TTHI) Report Updated: Feb 01, 2016 | Print This Page

Get more stock ratings by Louis Navellier

Transition Therapeutics Inc. (TTHI)

Rating: Sell Volatility: Aggressive
Total Grade: D Industry: Biotechnology
Competitors: SPHS, EXEL, EBS, AVXL

Stock Analysis

Rating: Monthly View

February March April May June July August September October November December January

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

Transition Therapeutics Inc.© quotemedia

Company Profile

Transition Therapeutics Inc., a biopharmaceutical company, engages in developing therapeutics for various disease indications primarily in Canada. Its product candidates include ELND005 (AZD-103), a Phase II clinical trial product for the treatment of Alzheimer’s disease and neuropsychiatric disorders; TT-301 and TT-302, which are in Phase I clinical trial for the treatment of rheumatoid arthritis, Alzheimer’s disease, intracerebral hemorrhage, and traumatic brain injury; and TT401/402, a Phase I clinical trial product to treat diabetes. The company also has a pipeline of preclinical and clinical drug candidates for the treatment of anti-inflammatory and metabolic indications. It has strategic collaborations with Elan Pharma International Limited to develop and commercialize ELND005 (AZD-103); and Eli Lilly and Company. The company was formerly known as Transition Therapeutics and Diagnostics Inc. and changed its name to Transition Therapeutics Inc. on December 2000. Transition Therapeutics Inc. was founded in 1987 and is headquartered in Toronto, Canada.

Recent News: Transition Therapeutics Inc.